LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/Xtant Medical Launches Three Novel Spinal Implants
Spine

Xtant Medical Launches Three Novel Spinal Implants

October 15, 2019 2 min read Premium comments

Advertisement

Xtant Medical Launches Three Novel Spinal Implants
Calix-C PC Plasma Coated PEEK Implant, Intice-C Titanium Cervical Interbody Spacer and Atrix-C Union Cervical Interbody Spacer / Courtesy of Xtant Medical Holdings, Inc.
Secondary#xtantmedical#cervicalinterbodydevice#cervicalimplants

Belgrade, Montana-based Xtant Medical Holdings, Inc., has announced the launch of three new spinal implants—two cervical interbody spacers and one plasma coated PEEK implant.

Kevin Brandt, Xtant’s chief commercialization officer, described the launches to OTW. “Even as we celebrate 20 years of meeting patient and physician needs in the spine and orthopedic indications, we continue to develop and commercialize new products that are designed to improve clinical outcomes. The three new products we are launching provide additional spacer options that surgeons can use to ensure that every patient receives a personalized surgical plan optimized to provide maximal benefit. We are excited to introduce these new products to the spine orthopedic community.”

The three new Xtant Medical products are:

  • Intice-C Titanium Cervical Interbody Spacer – “Utilizing a proprietary manufacturing technology, Intice-C implants provide all the biologic benefits of titanium without the related concerns of coating delamination possible with coated polyetheretherketone (PEEK) implants. With a modulus of elasticity similar to cancellous bone, the titanium architecture is designed to help mitigate concerns of stress shielding associated with rigid titanium implants. It also provides superior visualization compared with solid titanium implants.”
  • Atrix-C Union Cervical Interbody Spacer – “The Atrix-C Union is a cervical allograft interbody spacer that offers both cortical structural stability and a cancellous center. The combination of cortical and cancellous tissue provides an osteoconductive matrix designed to create an optimal environment for bone growth, and fusion. The Atrix-C Union allograft is available in three footprints and eight heights to accommodate a wide range of patient anatomy while providing a steady platform for fusion. Its pre-hydrated, ready-to-use packaging is tailored to reduce operating room time and increase graft strength during implantation.”
  • Calix-C PC Plasma Coated PEEK Implant – “The latest addition to the Calix PC product line, the Calix-C PC implant offers a new 5 -12 mm footprint. Consistent with the existing Calix PC implants, the Calix-C PC combines the osteo-equivalent modulus of PEEK with the bone qualities of titanium and offers frictional titanium plasma coating on bone contact areas. With the introduction of the Calix-C PC implant, physicians and patients have more implant size options from which to choose, helping to ensure that every patient has a surgical plan optimized for his or her cervical spine needs.”

Michael Mansfield, company director of marketing, told OTW, “We are very excited about our new product lines, which are on track for launch and will be used in surgical cases in the fourth quarter of this year. Atrix-C Union, one of three products, which we also introduced at NASS [North American Spine Society], has been implanted in multiple patients with positive user feedback.”

“We received very positive feedback about our new products at the just completed NASS and we will leverage this enthusiasm to capture additional market share moving forward.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy